19 November 2026Explainers with cited sources
OmnistuNews
Explainers

Two EU antibiotic-resistance targets are off track in ECDC's 2025 data; MRSA meets its target

Estimated EU bloodstream infection incidence rose 72% for carbapenem-resistant Klebsiella and 16.4% for a resistant E. coli group since 2019. These are population rates, not a patient's chance of infection.

AI-assisted summary of linked sources · 19 November 2026 · How we report

Original guide to ECDC EU bloodstream infection incidence estimates and targets; not patient riskOriginal guide to ECDC EU bloodstream infection incidence estimates and targets; not patient risk

Original Omnistu guide to ECDC estimates. EU incidence per 100,000 population, not resistance percentages or a patient risk calculator. Targets use the 2019 baseline.

The European Centre for Disease Prevention and Control (ECDC) and WHO/Europe published new antibiotic-resistance findings on 18 November 2026. Two of the EU's three bloodstream-infection reduction targets are off track in the 2025 estimates. The third, for meticillin-resistant Staphylococcus aureus (MRSA), has been reached at EU level, although recent increases threaten that progress.

The important distinction is what each number measures. The EU target indicators are estimated bloodstream infection incidence per 100,000 population. The broader WHO European Region figures describe the share of tested bacterial isolates that are resistant. Neither is the probability that a particular patient will acquire an infection or that their treatment will fail.

The three EU indicators, with their units

ECDC's full EARS-Net annual report, Tables 4 to 6, gives the following EU estimates. The 2030 targets use 2019 as their baseline:

These are the EU rows, not the EU/EEA rows. For example, the corresponding 2025 EU/EEA estimate for carbapenem-resistant K. pneumoniae is 3.70 per 100,000, not 3.75. The geographical labels matter when comparing a headline with a table.

The wider region tells a different kind of story

The joint executive summary combines EARS-Net data from 30 EU/EEA countries with CAESAR data from 17 other countries in the WHO European Region. Not every country reported every bacterium-antibiotic combination. WHO/Europe says 21 of 43 reporting countries had third-generation cephalosporin resistance in at least half of their tested K. pneumoniae isolates. For carbapenem resistance in that bacterium, the count was 10 of 43. For carbapenem-resistant Acinetobacter, it was 21 of 38.

Those are counts of countries crossing a resistance-percentage threshold among tested invasive isolates. They do not mean that half of all people, all infections, or all countries in the 53-member Region share the same risk. They also should not be placed on the same numerical scale as the EU incidence rates above.

Why surveillance limitations change the reading

We obtained the full EARS-Net report and read its methods, EU target analysis and tables, discussion and limitations, alongside the joint executive summary and both organizations' announcements. EARS-Net uses routine susceptibility results from blood and cerebrospinal-fluid isolates. In the de-duplicated data, more than 99% were from blood; the report uses these invasive isolates as a proxy for bloodstream infections.

The incidence estimates adjust for reported national population coverage. That coverage is itself estimated, and the incidence calculation does not adjust for differences in blood-culture sampling rates. National laboratory coverage, hospital and isolate representativeness, testing practices and changes over time can affect comparisons. ECDC also warns that changes in identifying and naming K. pneumoniae species may affect reported resistance percentages; the size of that effect is unknown. The latest report can revise earlier years, so these comparisons should use a consistent report rather than splice together older releases.

Euronews independently reported the release and discussed prevention with ECDC. Expert commentary published by SMC Spain also stresses the limited set of invasive infections and antimicrobials measured. These sources provide context, not an independent recalculation of the surveillance estimates. We have not reviewed every country appendix, reproduced ECDC's statistical models, or assessed a particular hospital.

Public-health priorities, not personal treatment advice

WHO/Europe and ECDC call for stronger infection prevention, laboratory capacity, surveillance and careful antibiotic use, with staffing and funding to support those measures. A national plan alone is not an outcome measure. The figures here do not show which antibiotic an individual needs, whether a specific infection is resistant, or what caused a particular country's change.

This is a summary of surveillance, not medical advice. Anyone with concerns about an infection or a prescribed antibiotic should ask their treating clinician; do not change treatment on the basis of these population figures.

More from Omnistu News